Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Teresita Bellido to Connexin 43

This is a "connection" page, showing publications Teresita Bellido has written about Connexin 43.

 
Connection Strength
 
 
 
2.444
 
  1. Plotkin LI, Bellido T. Beyond gap junctions: Connexin43 and bone cell signaling. Bone. 2013 Jan; 52(1):157-66.
    View in: PubMed
    Score: 0.480
  2. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008 Nov; 23(11):1712-21.
    View in: PubMed
    Score: 0.366
  3. Plotkin LI, Manolagas SC, Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem. 2002 Mar 08; 277(10):8648-57.
    View in: PubMed
    Score: 0.227
  4. Plotkin LI, Bellido T. Bisphosphonate-induced, hemichannel-mediated, anti-apoptosis through the Src/ERK pathway: a gap junction-independent action of connexin43. Cell Commun Adhes. 2001; 8(4-6):377-82.
    View in: PubMed
    Score: 0.213
  5. Davis HM, Pacheco-Costa R, Atkinson EG, Brun LR, Gortazar AR, Harris J, Hiasa M, Bolarinwa SA, Yoneda T, Ivan M, Bruzzaniti A, Bellido T, Plotkin LI. Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging Cell. 2017 06; 16(3):551-563.
    View in: PubMed
    Score: 0.164
  6. Pacheco-Costa R, Davis HM, Sorenson C, Hon MC, Hassan I, Reginato RD, Allen MR, Bellido T, Plotkin LI. Defective cancellous bone structure and abnormal response to PTH in cortical bone of mice lacking Cx43 cytoplasmic C-terminus domain. Bone. 2015 Dec; 81:632-643.
    View in: PubMed
    Score: 0.148
  7. Lezcano V, Bellido T, Plotkin LI, Boland R, Morelli S. Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate. Exp Cell Res. 2014 May 15; 324(1):30-9.
    View in: PubMed
    Score: 0.133
  8. Bivi N, Pacheco-Costa R, Brun LR, Murphy TR, Farlow NR, Robling AG, Bellido T, Plotkin LI. Absence of Cx43 selectively from osteocytes enhances responsiveness to mechanical force in mice. J Orthop Res. 2013 Jul; 31(7):1075-81.
    View in: PubMed
    Score: 0.124
  9. Bivi N, Condon KW, Allen MR, Farlow N, Passeri G, Brun LR, Rhee Y, Bellido T, Plotkin LI. Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res. 2012 Feb; 27(2):374-89.
    View in: PubMed
    Score: 0.115
  10. Lezcano V, Bellido T, Plotkin LI, Boland R, Morelli S. Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways. Arch Biochem Biophys. 2012 Feb 15; 518(2):95-102.
    View in: PubMed
    Score: 0.114
  11. Bivi N, Lezcano V, Romanello M, Bellido T, Plotkin LI. Connexin43 interacts with ├čarrestin: a pre-requisite for osteoblast survival induced by parathyroid hormone. J Cell Biochem. 2011 Oct; 112(10):2920-30.
    View in: PubMed
    Score: 0.112
  12. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011 Jul; 49(1):50-5.
    View in: PubMed
    Score: 0.104
  13. Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 2006 Sep; 39(3):443-52.
    View in: PubMed
    Score: 0.077
  14. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005 Feb 25; 280(8):7317-25.
    View in: PubMed
    Score: 0.070
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.